Clinical Trial Detail

NCT ID NCT01473095
Title Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors ArQule
Indications

lymphoma

Advanced Solid Tumor

Therapies

Miransertib

Age Groups: adult senior

No variant requirements are available.